EIGR - Eiger BioPharmaceuticals Inc Stock Price, Fair Value and News

$8.50

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

EIGR Price Action

Last 30 days

-15%

Last 90 days

-23.8%

Trailing 12 Months

-7.1%

EIGR RSI Chart

EIGR Valuation

Market Cap

12.6M

Price/Earnings (Trailing)

-0.27

Price/Sales (Trailing)

1.39

EV/EBITDA

0.08

Price/Free Cashflow

-0.27

EIGR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EIGR Fundamentals

EIGR Revenue

Revenue (TTM)

14.4M

EIGR Earnings

Earnings (TTM)

-75.0M

EIGR Profitability

Operating Margin

99.83%

EBT Margin

-522.31%

Return on Equity

-490.11%

Return on Assets

-193.07%

Free Cashflow Yield

-374.08%

EIGR Investor Care

Shares Dilution (1Y)

0.29%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	15.5M	14.6M	14.4M
2022	11.2M	13.2M	14.1M	13.5M
2021	0	0	0	12.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

CEO	Dr. David Apelian M.B.A., M.D., MBA, Ph.D.
WEBSITE	eigerbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	56

Eiger BioPharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Eiger BioPharmaceuticals Inc? What does EIGR stand for in stocks?

EIGR is the stock ticker symbol of Eiger BioPharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eiger BioPharmaceuticals Inc (EIGR)?

As of Mon Sep 30 2024, market cap of Eiger BioPharmaceuticals Inc is 12.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EIGR stock?

You can check EIGR's fair value in chart for subscribers.

Is Eiger BioPharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether EIGR is over valued or under valued. Whether Eiger BioPharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Eiger BioPharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EIGR.

What is Eiger BioPharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Sep 30 2024, EIGR's PE ratio (Price to Earnings) is -0.27 and Price to Sales (PS) ratio is 1.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EIGR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Eiger BioPharmaceuticals Inc's stock?

In the past 10 years, Eiger BioPharmaceuticals Inc has provided -0.468 (multiply by 100 for percentage) rate of return.